La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Alibaba Health Information Technology Résultats passés
Passé contrôle des critères 4/6
Alibaba Health Information Technology a connu une croissance annuelle moyenne de ses bénéfices de 52.3%, tandis que le secteur Consumer Retailing a vu ses bénéfices augmenter de en hausse à 21.1% par an. Les revenus ont augmenté de en hausse à un taux moyen de 28.2% par an. Le rendement des capitaux propres de Alibaba Health Information Technology est 6.1% et ses marges nettes sont de 3.3%.
Informations clés
52.3%
Taux de croissance des bénéfices
51.2%
Taux de croissance du BPA
| Consumer Retailing Croissance de l'industrie | 28.3% |
| Taux de croissance des recettes | 28.2% |
| Rendement des fonds propres | 6.1% |
| Marge nette | 3.3% |
| Dernière mise à jour des bénéfices | 31 Mar 2024 |
Mises à jour récentes des performances passées
Recent updates
Alibaba Health Information Technology (HKG:241) Is Looking To Continue Growing Its Returns On Capital
Jul 03
After Leaping 26% Alibaba Health Information Technology Limited (HKG:241) Shares Are Not Flying Under The Radar
Jun 07Alibaba Health Information Technology's (HKG:241) Solid Earnings Are Supported By Other Strong Factors
Jun 06Risks Still Elevated At These Prices As Alibaba Health Information Technology Limited (HKG:241) Shares Dive 26%
Apr 21Is Now The Time To Look At Buying Alibaba Health Information Technology Limited (HKG:241)?
Apr 16Alibaba Health Information Technology (HKG:241) Might Have The Makings Of A Multi-Bagger
Mar 29Is There An Opportunity With Alibaba Health Information Technology Limited's (HKG:241) 36% Undervaluation?
Mar 12With A 25% Price Drop For Alibaba Health Information Technology Limited (HKG:241) You'll Still Get What You Pay For
Jan 17Is Now An Opportune Moment To Examine Alibaba Health Information Technology Limited (HKG:241)?
Jan 07Returns On Capital Are Showing Encouraging Signs At Alibaba Health Information Technology (HKG:241)
Dec 15Shareholders Should Be Pleased With Alibaba Health Information Technology Limited's (HKG:241) Price
Sep 28Alibaba Health Information Technology Limited's (HKG:241) Intrinsic Value Is Potentially 25% Below Its Share Price
Jul 02Is Alibaba Health Information Technology Limited (HKG:241) Potentially Undervalued?
Jun 11Estimating The Fair Value Of Alibaba Health Information Technology Limited (HKG:241)
Jun 22Is There An Opportunity With Alibaba Health Information Technology Limited's (HKG:241) 49% Undervaluation?
Dec 01Alibaba Health Information Technology (HKG:241) Is Looking To Continue Growing Its Returns On Capital
Oct 15Estimating The Fair Value Of Alibaba Health Information Technology Limited (HKG:241)
Aug 12Alibaba Health Information Technology (HKG:241) Is Doing The Right Things To Multiply Its Share Price
Jun 25These Analysts Just Made A Huge Downgrade To Their Alibaba Health Information Technology Limited (HKG:241) EPS Forecasts
May 30Earnings Report: Alibaba Health Information Technology Limited Missed Revenue Estimates By 6.8%
May 27The Return Trends At Alibaba Health Information Technology (HKG:241) Look Promising
Mar 23Should You Be Adding Alibaba Health Information Technology (HKG:241) To Your Watchlist Today?
Mar 05How Much Are Alibaba Health Information Technology Limited (HKG:241) Insiders Taking Off The Table?
Feb 15Are Alibaba Health Information Technology's (HKG:241) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Jan 31
If You Had Bought Alibaba Health Information Technology (HKG:241) Stock Three Years Ago, You Could Pocket A 457% Gain Today
Dec 31Has Alibaba Health Information Technology Limited's (HKG:241) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Dec 16Will Alibaba Health Information Technology's (HKG:241) Growth In ROCE Persist?
Dec 01Ventilation des recettes et des dépenses
Comment Alibaba Health Information Technology gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 24 | 27,027 | 883 | 4,550 | 705 |
| 31 Dec 23 | 27,623 | 851 | 4,943 | 689 |
| 30 Sep 23 | 28,218 | 817 | 5,336 | 673 |
| 30 Jun 23 | 27,491 | 675 | 5,196 | 675 |
| 31 Mar 23 | 26,763 | 536 | 5,055 | 678 |
| 31 Dec 22 | 24,742 | 332 | 4,701 | 704 |
| 30 Sep 22 | 22,720 | 128 | 4,346 | 730 |
| 30 Jun 22 | 21,649 | -69 | 4,410 | 729 |
| 31 Mar 22 | 20,578 | -266 | 4,474 | 729 |
| 31 Dec 21 | 19,146 | -216 | 4,171 | 623 |
| 30 Sep 21 | 17,714 | -167 | 3,868 | 517 |
| 30 Jun 21 | 16,616 | 91 | 3,501 | 470 |
| 31 Mar 21 | 15,518 | 349 | 3,135 | 424 |
| 31 Dec 20 | 14,080 | 313 | 2,836 | 385 |
| 30 Sep 20 | 12,642 | 278 | 2,537 | 347 |
| 30 Jun 20 | 11,119 | 136 | 2,289 | 300 |
| 31 Mar 20 | 9,596 | -7 | 2,041 | 253 |
| 31 Dec 19 | 8,465 | -3 | 1,833 | 252 |
| 30 Sep 19 | 7,334 | 1 | 1,624 | 250 |
| 30 Jun 19 | 6,215 | -40 | 1,416 | 235 |
| 31 Mar 19 | 5,096 | -82 | 1,208 | 219 |
| 31 Dec 18 | 4,264 | -91 | 1,034 | 194 |
| 30 Sep 18 | 3,432 | -100 | 859 | 169 |
| 30 Jun 18 | 2,937 | -104 | 760 | 147 |
| 31 Mar 18 | 2,443 | -107 | 661 | 126 |
| 31 Dec 17 | 1,876 | -152 | 563 | 123 |
| 30 Sep 17 | 1,310 | -196 | 465 | 120 |
| 30 Jun 17 | 892 | -202 | 371 | 114 |
| 31 Mar 17 | 475 | -208 | 276 | 109 |
| 31 Dec 16 | 285 | -201 | 233 | 99 |
| 30 Sep 16 | 94 | -194 | 191 | 90 |
| 30 Jun 16 | 76 | -193 | 182 | 83 |
| 31 Mar 16 | 57 | -192 | 173 | 76 |
| 31 Dec 15 | 44 | -173 | 175 | 68 |
| 30 Sep 15 | 32 | -154 | 177 | 60 |
| 30 Jun 15 | 31 | -118 | 145 | 47 |
| 31 Mar 15 | 30 | -81 | 113 | 34 |
| 31 Dec 14 | 31 | -60 | 74 | 29 |
| 30 Sep 14 | 31 | -39 | 35 | 23 |
| 30 Jun 14 | 27 | -36 | 35 | 19 |
| 31 Mar 14 | 22 | -31 | 33 | 14 |
| 31 Dec 13 | 16 | -35 | 34 | 7 |
| 30 Sep 13 | 12 | -39 | 36 | 0 |
Des revenus de qualité: 241 a un important ponctuel perte de CN¥293.9M impactant ses 12 derniers mois de résultats financiers à 31st March, 2024.
Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de 241 (3.3%) sont supérieures à celles de l'année dernière (2%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: 241 est devenue rentable au cours des 5 dernières années, augmentant ses bénéfices de 52.3% par an.
Accélération de la croissance: La croissance des bénéfices de 241 au cours de l'année écoulée ( 64.9% ) dépasse sa moyenne sur 5 ans ( 52.3% par an).
Bénéfices par rapport au secteur d'activité: La croissance des bénéfices 241 au cours de l'année écoulée ( 64.9% ) a dépassé celle du secteur Consumer Retailing 1.6%.
Rendement des fonds propres
ROE élevé: Le retour sur capitaux propres de 241 ( 6.1% ) est considéré comme faible.